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Background: The ivermectin-binding site on the 
glutamate-gated chloride channel was recently 
resolved by crystallography. 
Results: Ivermectin binds in a similar orientation to 
the structurally-related glycine receptor although 
two H-bonds apparent in the crystal structure proved 
unimportant for binding to glycine receptors. 
Conclusion: Ivermectin binding mechanisms vary 
among Cys-loop receptors. 
Significance: Understanding ivermectin binding 
mechanisms may help in designing new drugs. 
 
SUMMARY 
Ivermectin is an important anthelminthic drug 
that works by activating glutamate-gated 
chloride channel receptors (GluClRs) in 
nematode parasites. GluClRs belong to the Cys-
loop receptor family that also includes glycine 
receptor (GlyR) chloride channels. GluClRs and 
A288G mutant GlyRs and are both activated by 
nanomolar ivermectin concentrations. The 
crystal structure of the C. elegans α  GluClR 
complexed with ivermectin has recently been 
published. Here we investigated the ivermectin 
binding site on the α1  GlyR using site-directed 
mutagenesis and electrophysiology. Based on a 
mutagenesis screen of residues in the M1-M3 
transmembrane domains, we identified A288 and 
P230 as crucial ivermectin sensitivity 
determinants. A comparison of the actions of 
selamectin and ivermectin suggested the 
benzofuran C05-OH moiety was crucial for the 
binding interaction. When taken together with 
docking simulations, these results provided 
independent support for a GlyR ivermectin 
binding orientation similar to that seen in the 
GluClR crystal structure. Whereas the crystal 
structure shows that ivermectin interacts with the 
α  GluClR via H-bonds with L218, S260 and T285 
(α  GluClR numbering), our data indicate that H-
bonds with residues homologous to S260 and 
T285 are not important for high ivermectin 
sensitivity or direct agonist efficacy in A288G α1  
GlyRs or three other GluClRs. Our data also 
suggest that van der Waals interactions between 
the ivermectin disaccharide and GlyR M2-M3 
loop residues are unimportant for high 
ivermectin sensitivity. Thus, although our results 
independently corroborate the ivermectin 
binding orientation as revealed by the crystal 
structure, they demonstrate that some of the 
binding interactions revealed by this structure do 
not pertain to other highly ivermectin-sensitive 
Cys-loop receptors. 
 
Ivermectin is a semi-synthetic anthelmintic drug 
used widely in human medicine and veterinary 
practice (1). The biological target for ivermectin and 
related macrocyclic lactones is a glutamate-gated 
chloride channel receptor (GluClR) that is expressed 
in the neurons and muscle cells of nematodes and 
some arthropods but is absent in vertebrates (2). 
Ivermectin irreversibly activates these GluClRs at 
low nanomolar concentrations, thereby inhibiting 
neuronal activity and muscle contractility and thus 
inducing death by flaccid paralysis (3). 
Unfortunately, ivermectin resistance is emerging as 
a serious problem in nematodes and arthropods (4-
6). In several instances, resistance has been shown to 
be caused by mutations that reduce the GluClR 
ivermectin sensitivity (7-9). Insight into the binding 
mechanisms of ivermectin at the GluClR may 
 2 
contribute to the understanding of ivermectin 
resistance mechanisms and to the development of a 
much-needed new generation of anthelmintic drugs. 
A 3.3 Å crystal structure of the C. elegans α GluClR 
with ivermectin bound has recently been published 
(10), revealing ivermectin’s molecular interactions 
at atomic resolution. 
GluClRs belong to the Cys-loop receptor 
superfamily which also includes the excitatory 
nicotinic acetylcholine (nAChR) and 5-
hydroxytryptamine type 3 receptors (5-HT3R), the 
inhibitory γ-aminobutyric acid type A receptor 
(GABAAR) and the inhibitory GlyR. Cys-loop 
receptors are formed by five homologous subunits 
that each consist of an N-terminal ligand-binding 
domain (LBD) and a bundle of four transmembrane 
helices (M1-M4) that comprise the transmembrane 
domain (TMD). M2 helices contributed from each 
subunit line the central ion channel pore. 
Neurotransmitter ligand-binding sites lie at the 
interface of LBDs of adjacent subunits.  
Ivermectin also interacts with many 
vertebrate Cys-loop receptors, but usually only at 
high (micromolar) concentrations. For example, 
GABAARs and GlyRs are directly activated by 
ivermectin at 1-2 µM (11,12) and acetylcholine-
induced currents at α7 nAChRs are facilitated by a 
pre-application of 30 µM ivermectin (13,14). Insight 
into the binding mechanisms of ivermectin at human 
Cys-loop receptors may contribute to the 
characterization of novel therapeutic 
pharmacophores. For this reason, we sought to 
identify the molecular basis of ivermectin binding to 
the α1 GlyR. 
The α GluClR-ivermectin crystal structure 
(10) was published after experiments described in 
Figs. 1-7A were completed. With prior knowledge 
of the crystal stucture, our experimental design 
would have been different. However, because all of 
our data remain relevant, we describe our original 
experiments in the context of the original 
experimental design. Following this, we generate a 
structural model of the α1 GlyR ivermectin binding 
site on the basis of our data, compare it with the 
crystal structure binding site and then 
experimentally verify whether it can account for 
ivermectin binding to the α1 GlyR. 
 
EXPERIMENTAL PROCEDURES 
 
Molecular Biology – The human α1 GlyR subunit 
and the Haemonchus contortus GluClR α3Β subunit 
cDNAs were subcloned into the pCIS and 
pcDNA3.1 plasmid vectors, respectively. Site-
directed mutagenesis was performed using the 
QuikChange mutagenesis kit (Stratagene, La Jolla, 
CA, USA) and the successful incorporation of 
mutations was confirmed by DNA sequencing. 
HEK-293 cell culture and transfection – HEK-293 
cells were cultured in Dulbecco’s Modified Eagle’s 
medium (Gibco, Grand Island, NY, USA) 
containing Serum Supreme (Lonza, Walkersville, 
MD, USA) and penicillin/streptomycin (P/S; Sigma-
Aldrich, St. Louis, MO, USA) and split onto glass 
coverslips in 35 mm culture dishes. On the 
following day, cells were transiently transfected via 
a calcium phosphate method with the GlyR or 
GluClR cDNAs together with empty pEGFP 
plasmid vector (Clontech, Mountainview, CA, USA) 
as a fluorescent transfection marker. Typically, 250 
ng of each plasmid was used to transfect each 3 cm 
dish. After 12-18 hours in the transfection medium, 
cells were washed twice with calcium-free 
phosphate-buffered saline and returned to DMEM. 
Cells were used in experiments 24-48 hours later. 
Electrophysiology and data analysis – An inverted 
fluorescence microscope was used to visualize cells 
for electrophysiological experiments. Cells 
expressing recombinant GluClRs or GlyRs were 
identified by their green fluorescence. Borosilicate 
glass capillary tubes (Vitrex, Modulohm, Denmark) 
and a horizontal pipette puller (P97, Sutter 
Instruments, Novato, CA, USA) were used to pull 
patch clamp pipettes with tip resistances of 2-3 MΩ 
when filled with pipette solution consisting of (in 
mM): 145 CsCl, 2 CaCl2, 2 MgCl2, 10 HEPES and 
10 EGTA, adjusted to pH 7.4 with 2 M NaOH. Drug 
solutions were prepared from the control solution 
consisting of (in mM): 140 NaCl, 5 KCl, 2 CaCl2, 1 
MgCl2, 10 HEPES and 10 D-glucose, adjusted to pH 
7.4 with 2 M NaOH. Cells were voltage-clamped at -
40 mV in the whole-cell recording configuration and 
membrane currents were recorded using an Axon 
Multiclamp 700B amplifier and pClamp 10 software 
(Molecular Devices, Sunnyvale, CA, USA). 
Membrane currents were filtered at 500 Hz and 
digitized at 2 kHz. Stocks of glycine and L-
glutamate, dissolved in water to 1 M and adjusted to 
pH 7.4 with NaOH, were maintained at 4 °C. 
Ivermectin (Sigma-Aldrich, St Louis, MO, USA) 
and selamectin (a gift from Pfizer Inc, Milwaukee, 
WI, USA) were dissolved in dimethyl sulfoxide and 
stored as 10 mM stocks at -20 °C. Thus, solutions 
containing 30 µM ivermectin (the highest 
concentration routinely used) also contained 0.3 % 
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dimethyl sulfoxide. This concentration of dimethyl 
sulfoxide showed no effects on the membrane 
resistance of cells. Solutions were applied to cells 
via a gravity-induced perfusion systems fabricated 
from polyethylene tubing. All experiments were 
performed at room temperature (19 - 22 °C). 
Agonist dose-response experiments were performed 
as described below. For each dose-response 
experiment, the half-maximal agonist concentration 
(EC50), Hill coefficient (nH) and saturating current 
magnitude (Imax) values were determined by fitting 
individual dose-response relationships with the 3-
parameter Hill equation (Sigmaplot 11, Jandel 
Scientific, San Rafael, CA, USA). Results are 
expressed as mean ± S.E.M from at least 3 
experiments. Unpaired t-tests (Sigmaplot 11, Jandel 
Scientific, San Rafael, CA, USA) were used to 
compare these values, as described in the Table 
legends. 
GlyR structural modelling and computational 
docking – A homology model of the α1 GlyR 
pentamer was built based on a hybrid template, with 
the TMD and Cys-loop based on the bacterial ELIC 
channel structure (pdb code: 2VL0) (15) and the 
remainder of the LBD based on acetylcholine 
binding protein (AChBP) (pdb code 1I9B) (16), as 
described previously (17). Two distinctly different 
families of ivermectin conformers were predicted by 
MarvinSketch software (Chemaxon, Budapest, 
Hungary). AutoDock Vina (18) was used to explore 
feasible interactions of each of these two conformer 
families with WT and A288G mutant model GlyRs, 
within a 40 x 40 x 30 Å box surrounding the A288 
residue. Conformer 1 gave consistently stronger 
binding energies than conformer 2 in all docking 
experiments so only the results for conformer 1 are 
presented here. 
Following the publication of the α GluClR-
ivermectin crystal structure (10), in which the bound 
ivermectin was in the conformer 1 family, we built a 
new homology model of the α1 GlyR pentamer 
based on this structure (3RIF). Ivermectin in 
conformer 1 was then docked to this model, as 
described above. As a control, equivalent docking 
was carried out on 3RIF from which the bound 
ivermectin had been removed prior to docking.  
 
RESULTS 
 
Disruption of ivermectin efficacy via mutations at 
the LBD-TMD interface  
Because the conservative Y279F mutation in 
the α1 GlyR M2-M3 loop dramatically reduces 
ivermectin sensitivity (19), we investigated whether 
residues at the LBD-TMD interfacial region may 
contribute to ivermectin binding or gating 
mechanisms. We thus introduced cysteines one-at-a-
time for each residue from R271C (19’) to I283C. 
Each mutant GlyR was investigated by quantitating 
the steady-state current magnitude activated by 0.3, 
3 and 30 µM ivermectin as a fraction of the 
saturating glycine-activated current in the same cell 
(Fig. 1A). The wild type (WT) α1 GlyR was 
included as a positive control. Mean glycine EC50 
values and peak current magnitudes of all mutant 
receptors have previously been reported (20). As 
shown in Fig. 1A, most mutant GlyRs showed little 
or no activation at 0.3 µM ivermectin but strong 
activation at 30 µM ivermectin. Apart from Y279F, 
P275C was the only mutation significantly reduced 
the magnitude of the current activated by 3 µM 
ivermectin relative to the corresponding value 
observed at the WT GlyR (P<0.05). The locations of 
P275 and Y279 in an α1 GlyR structural homology 
model are shown in Fig. 1B. We next quantitated the 
ivermectin EC50 values for the P275C and Y279F 
mutant GlyRs. As ivermectin is a poorly reversible 
agonist and does not produce appreciable 
desensitization (12,21), dose-responses were 
quantitated by applying progressively increasing 
ivermectin concentrations. Examples of the 
responses of WT and Y279F mutant GlyRs to 
saturating concentrations of glycine and 
progressively increasing concentrations of 
ivermectin are shown in Fig. 1C. Averaged 
ivermectin dose-response relationships for both 
receptors are shown in Fig. 1E with mean 
parameters of best fit summarized in Table 1. Both 
mutations dramatically reduced receptor sensitivty to 
both ivermectin and glycine (Tables 1 and 2). Unlike 
Y279F, the Y279C mutation had little effect on 
ivermectin sensitivity (Table 1) but produced a large 
rightward shift in the glycine EC50 (19,20).  
We next investigated possible ivermectin 
sensitivity determinants in the LBD regions (i.e., 
loop 2, conserved Cys-loop pre-M1 domain) that lie 
proximal to P275 and Y279 in our model α1 GlyR 
structure. In loop 2, we investigated A52C and E53C 
not only because of their proximity to Y279 but also 
because of the known role of A52 as an alcohol 
determinant (22,23). We also investigated D141G, 
L142C and K143C in the conserved Cys-loop and 
Y222C and Y223C in the pre-M1 domain. 
Ivermectin dose-responses were quantitated for all 
mutant GlyRs, with sample ivermectin-induced 
currents for the L142C mutant GlyR shown in Fig. 
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1C. Averaged parameters of best fit for this and all 
other mutant GlyRs are summarized in Table 1. The 
L142C and Y222C mutations dramatically reduced 
receptor sensitivity to both ivermectin and glycine 
(Table 1 and 2, Fig. 1E). Given this non-selective 
action on glycine- and ivermectin-mediated currents, 
and the locations of these mutations in known 
agonist transduction pathways (24), we hypothesized 
that these mutations disrupted the ivermectin gating 
efficacy. To test this, we quantitated the potency 
with which ivermectin facilitated glycine-activated 
currents. This was performed by alternating low 
(EC5 – EC10) glycine applications with 5 s 
applications of increasing ivermectin concentrations 
(Fig. 1D). Averaged ivermectin facilitatory dose-
response relationships for the WT, L142C, Y222C, 
P275C and Y279F GlyRs reveal that the facilitatory 
effects of ivermectin occurred at lower 
concentrations at these mutant GlyRs than at the WT 
GlyR (Fig. 1F, Table 3). Together, these results 
indicate that the L142C, Y222C, P275C and Y279F 
substitutions disrupt ivermectin efficacy while 
having little effect on its affinity. 
We then tested the effects of these mutations 
on the highly ivermectin-sensitive A288G mutant 
GlyR (21). As summarized in Table 4, the A288G 
mutation adds to the deleterious effect of these 
mutations on ivermectin efficacy. 
 
Identification of TMD residues that influence 
ivermectin sensitivity 
We have already shown that the A288F 
mutation eliminates ivermectin agonist sensitivity 
(25). However, it has yet to be investigated whether 
this mutation also affects the sensitivity with which 
ivermectin facilitates glycine currents. Using a 
protocol as described in Fig. 1D, we observed 
significant facilitation of glycine-gated currents only 
at ivermectin concentrations > 10 µM (Fig. 2A,B). 
This is consistent with A288F disrupting an 
ivermectin binding site. 
As discussed below, our GlyR model places 
A288 near the extracellular end of M3, facing across 
the subunit interface towards M1 of the adjacent 
subunit. From our ELIC-based model, we identified 
ten residues as having sidechains near to or directed 
towards A288: six in the M1 domain (I225, Q226, 
I229, P230, L233, I234); three M2 sidechains that 
face away from the channel pore (V260, T264, Q266 
which correspond to the 8’, 12’ and 16’ positions, 
respectively) and an M3 residue, L291, located one 
helical turn below A288. We individually mutated 
each of these residues to tryptophan, on the grounds 
that the bulky tryptophan sidechain may occlude 
access to a putative ivermectin binding site in the 
vicinity of A288. Tryptophan substitution has been 
employed at GABAARs to elucidate transmembrane 
domain binding sites for alcohols and anesthetics 
(30,31), at nAChRs to define transmembrane helical 
structure and dynamics (32,33) and at P2X receptors 
to investigate movements induced by ivermectin 
(34). Glycine dose-response relationships were 
quantitated for all these mutant GlyRs to establish 
whether the substitutions were well-tolerated by the 
receptor. As cells transfected with the I234W mutant 
GlyR exhibited no response to glycine or ivermectin, 
this mutant was not investigated further. Averaged 
dose-responses for M1 domain mutant GlyRs are 
shown in Fig. 3A (left panel) with parameters of best 
fit summarized in Table 2. Similarly, averaged dose-
responses for GlyRs incorporating mutations in the 
M2 or M3 domains are shown in Fig. 3B (left panel) 
with mean parameters of best fit summarized in 
Table 2. Mean glycine EC50 values of all mutant 
GlyRs were within an order of magnitude of the WT 
GlyR value, although significant reductions in Imax 
were observed at both the V260W and T264W 
GlyRs (Table 2). 
Mean ivermectin dose-response 
relationships for these mutants are plotted in Fig. 3A 
and B (right panels), with averaged parameters of 
best fit summarized in Table 1. Sample ivermectin 
dose-response relationships for the I229W, P230W 
and L233W mutant GlyRs are shown in Fig. 3C. 
Most mutants did not differ significantly from WT 
in their ivermectin sensitivity. However, the P230W 
GlyR exhibited a significantly increased ivermectin 
EC50 value and a significantly reduced Imax relative 
to the WT GlyR value (Table 1). On the other hand, 
at the Q226W mutant GlyR, maximal ivermectin-
activated currents were significantly larger than the 
WT GlyR value although ivermectin sensitivity was 
significantly decreased (Table 1). These results 
implicate Q226 and P230 as ivermectin sensitivity 
determinants. The L233W, L291W, T264W mutant 
GlyRs were not activated by ivermectin at 
concentrations of up to 100 µM (Fig. 3C, Table 1).  
At the L233W and L291W mutant GlyRs 
we noticed that responses to saturating glycine were 
reduced in magnitude or even absent when glycine 
was applied after ivermectin (e.g., Fig. 3C). At both 
mutant GlyRs, a 5 s application of 10 µM ivermectin 
caused a significant (P<0.05) decrease in the time 
taken for glycine-activated current to decay to half 
maximum amplitude (Fig. 4A, B). In addition, 
subsequent glycine-activated currents were 
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dramatically decreased in magnitude (Fig. 4A). This 
effect of ivermectin proved to be irreversible. 
Although single applications of 1 or 3 µM 
ivermectin had little effect on peak glycine-activated 
current magnitude, repeated applications of 1 µM 
ivermectin produced a slowly-developing but 
consistent increase in the desensitization rate (not 
shown). Unfortunately, the slow onset and 
irreversibility of this effect made it difficult to 
quantitate its ivermectin sensitivity. To determine 
whether Leu residues at positions L233 and L291 
positions were specifically required for ivermectin to 
exert an agonist effect, we investigated the effects of 
ivermectin on the highly non-conservative L233Q 
and L291Q mutant GlyRs. As summarized in Table 
1, ivermectin activated both receptors with EC50 and 
Imax values that were not significantly different from 
WT values. Thus, the desensitization-enhancing 
effect of ivermectin appears to require bulky 
tryptophan sidechains at either of the two sites. In 
the model presented below, these two residues lie 
opposite each other across the intersubunit interface. 
The T264W (12’) mutant GlyR responded in 
an unusual manner to both glycine and ivermectin. 
Glycine activated a transient inward current that was 
followed by a distinct upward deflection that 
persisted for the duration of the glycine application 
(Fig. 4C). Consistent with a previous study that 
observed a similar phenomenon in mutant 
homomeric ρ1 GABAARs (35), we speculate that 
prolonged glycine application inhibited a leak 
current through these receptors. Ivermectin produced 
an irreversible dose-dependent inhibition of this leak 
current (Fig. 4C), with a mean IC50 of 2.5 ± 1.4 µM 
and an nH value of 1.3 ± 0.2 (both n=4). This IC50 
value, which is not significantly different from the 
WT value, suggests that ivermectin sensitivity is not 
dramatically affected by the mutation.  
We next tested whether the M1 domain 
tryptophan substitutions impaired ivermectin 
sensitivity in the A288G mutant GlyR. Whereas the 
P230W mutation produced an ivermectin EC50 value 
7-fold higher than the WT value, the P230W/A288G 
value (5.6 ± 0.3 µM) was 175-fold greater than the 
value of 0.032 ± 0.008 µM at the A288G mutant 
GlyR. Similarly, mutations of residues surrounding 
P230 on the same face of M1, I225W/A288G, 
Q226W/A288G and I229W/A288G mutant GlyRs 
exhibited EC50 values five- to eight-fold higher than 
A288G mutant GlyR alone, whereas the single 
mutants did not differ from WT values (Table 4). 
Thus, P230 emerges as a crucial ivermectin 
sensitivity determinant at the A288G mutant GlyR. 
As discussed below, the above results are 
consistent with ivermectin binding at the M3 – M1 
intersubunit interface. As several other residues in 
this region have previously been implicated as 
binding sites for alcohols, anaesthetics and 
neurosteroids in GABAARs and GlyRs, we tested 
whether these residues may also comprise 
ivermectin binding sites. As S267 (at the 15’ 
position of the M2 domain) in the α1 GlyR has been 
implicated as an alcohol binding site (36,37), we 
investigated the ivermectin sensitivity of the S267I 
mutant GlyR. As summarized in Table 1, this mutant 
GlyR exhibited an identical ivermectin sensitivity to 
the WT GlyR, although it did show a tendency 
towards higher Imax and nH values. The potency with 
which ivermectin facilitated EC10 glycine currents at 
the S267I mutant GlyR was also similar to WT 
(Table 3). Thus, S267 does not contribute to an 
ivermectin site. In the GABAAR, an α1 subunit M1 
domain 12’ Thr residue (corresponding to I234 in 
the GlyR) has been proposed to contribute to an 
intersubunit neurosteroid site that is eliminated via 
the Thr–to-Ile mutation and only slightly altered by 
the Thr-to-Ser mutation (38). As the α1 GlyR 
contains an endogenous Ile at this position, we 
investigated the effect of the reverse I234S mutation. 
As shown in Table 1, this mutation had no effect on 
ivermectin sensitivity. A GABAAR etomidate 
binding determinant at an α-subunit Met residue 
corresponding to L233 in the α1 GlyR (27) can also 
be eliminated as a potential ivermectin sensitivity 
determinant on the grounds that the L233Q mutation 
had no effect on ivermectin potency (Table 1). 
Finally, a GABAAR neurosteroid binding site at a 
β2-subunit Tyr residue corresponding to W286 at 
the GlyR was shown to be eliminated by a Tyr-to-
Phe substitution (38). However, the α1 GlyR 
W286F mutation produced only a moderate (two-
fold) increase in the ivermectin EC50 value (Table 
1). We also investigated the less conservative 
W286A mutation but it did not express. Thus, we 
conclude that none of these residues are likely to 
contribute to an ivermectin binding site.  
 
Evidence for an ivermectin binding site spanning 
adjacent subunits 
To discriminate experimentally between 
intrasubunit and intersubunit locations of the 
ivermectin binding site, we examined the ivermectin 
sensitivity of GlyRs formed from co-expression of 
P230W/A288G and A288F mutant subunits, which 
have low (5.6 µM) or no ivermectin sensitivity, 
respectively. Our rationale was that if the ivermectin 
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binding site is formed within a single subunit, then 
the resulting mixed receptors should be ivermectin-
insensitive (i.e. EC50 > 5 µM) as each subunit is 
individually ivermectin-insensitive. Alternately, if 
the resultant recombinant receptors are potently 
activated by ivermectin, then this site must be 
formed at those subunit interfaces that contain the 
two residues “permissive” for ivermectin sensitivity;  
(+) M3 288-Gly (from P230W/A288G mutant) and 
(-) M1 230-Pro (from A288F mutant). Assuming 
subunits recombine randomly to produce receptors 
with all possible stoichiometries, the number of 
putative intersubunit ivermectin sites (i.e., interfaces 
containing G288 on one face and P230 on the other) 
will range from 0 to 2 per receptor (17). As shown in 
the example in Fig. 5A, ivermectin did indeed 
potently activate currents in receptors formed by co-
expression of P230W/A288G and A288F mutant 
subunits. These currents exhibited a mean 
ivermectin EC50 value of 0.7 ± 0.3 µM, an nH of 1.5 
± 0.1 and an Imax of 3.1 ± 1.0 nA (all n = 4). This 
EC50 shows higher sensitivity than the sensitivity of 
each subunit when expressed alone (Fig. 5B), 
suggesting that ivermectin sites are located at 
subunit interfaces and that potent receptor activation 
can be achieved with two bound ivermectin 
molecules. Our model below places these two 
residues directly opposite each other at the opening 
to a cavity at the intersubunit interface. 
 
Selamectin exhibits reduced agonist efficacy at the 
α1 GlyR and α3B GluClR 
In an attempt to define the molecular 
interaction between ivermectin and the GlyR, we 
sought to identify moieties crucial for its potency 
and efficacy. We previously showed that the direct 
agonist EC50 and Imax values for doramectin, 
emamectin, eprinomectin and moxidectin did not 
differ significantly from those for ivermectin at 
either the WT or A288G GlyRs (21). All these 
compounds share a common structure at the 
benzofuran moiety but vary in structure at other 
groups. As selamectin differs in structure from these 
compounds at the benzofuran moiety, we compared 
the effects of selamectin and ivermectin at the α1 
GlyR. Selamectin contians an NOH group at the C5 
position whereas the other derivatives contain an OH 
group (abbreviated hereafter as C05-NOH and C05-
OH, respectively). Selamectin, at concentrations up 
to 30 µM, activated no current at the WT GlyR. 
However, as shown in the example in Fig. 6A, it 
potently facilitated glycine currents. The averaged 
selamectin facilitatory dose-response relationship, 
together with that for ivermectin reproduced from 
Fig. 1F, is shown in Fig. 6B. Selamectin facilitation 
exhibited a mean EC50 of 3.6 ± 0.9 µM and an nH of 
3.2 ± 0.7 (both n=5). As both values did not differ 
significantly from those for ivermectin at the WT 
GlyR (Table 4), we tentatively conclude that 
selamectin binds with a similar potency to 
ivermectin but is unable to directly gate the receptor. 
The A288G GlyR was directly activated by 
selamectin with a mean EC50 value of 2.0 ± 0.3 µM, 
an nH value of 2.1 ± 0.1 and an Imax of 2.6 ± 0.2 nA 
(all n=4). This selamectin EC50 value was 
significantly higher than that of ivermectin at this 
mutant GlyR (P<0.001, Fig. 6D). As this low 
potency appears incompatible with its known 
efficacy as an anthelmintic (39), we investigated the 
selamectin potency at the H. contortus α3B GluClR 
(40). These receptors were activated by selamectin 
(Fig. 6C, D), with an EC50 value of 0.34 ± 0.06 µM, 
an nH of 2.3 ± 0.4 and an Imax of 1.3 ± 0.3 nA (all 
n=5). Again, this EC50 value is significantly higher 
than that for ivermectin at the same receptor 
(P<0.001). The difference between ivermectin and 
selamectin sensitivites at the GluClR is less than that 
observed at the GlyR, which is to be expected given 
that selamectin is an effective anthelmintic with a 
large margin of safety in vertebrates (39,41). 
 
Molecular modeling of a putative ivermectin binding 
site 
To model the ivermectin-binding site, we 
carried out computational docking of ivermectin to 
our ELIC-based (2VL0) α1 GlyR model within a 
large box surrounding A288. We found no 
significant differences in docking results in the WT 
relative to the A288G mutant GlyR (Fig 7A-C). As 
noted above, A288 and P230 (shown in red and 
magenta, respectively) face each other across the 
subunit interface, either side of the opening to a 
cavity at the inter-subunit interface. We 
hypothesized that the ivermectin-binding site may be 
within this cavity but access of ivermectin to the 
cavity may require significant conformational 
change, not catered for in our model, even though 
we allowed flexible sidechains for seven residues 
surrounding A288. Consistent with this hypothesis 
of a cavity site, T264 (from (+) side, shown in 
green) and Q266 (from (-) side, shown in blue) 
contribute to the lining of the cavity and Trp 
substitutions of these residues caused an inhibitory 
effect of ivermectin and an increased ivermectin 
sensitivity, respectively.  Other residues that, in the 
A288G backround, showed reduced ivermectin 
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sensitivity when substituted with Trp, I225, Q226 
and I229, also surround the entrance to the cavity 
(shown in light pink). The residues L233 and L291 
(shown in yellow), that when substituted with Trp, 
abolished activation by ivermectin but retained 
sensitivity to ivermectin in the form of increased 
desensitization, also face each other across the 
subunit interface one helical turn below P230 and 
A288, respectively. 
Our binding site hypothesis independently 
corroborates the recently published α GluClR crystal 
structure with ivermectin bound (10). We then 
employed the same procedure as above to dock 
ivermectin onto a model of the α1 GlyR based on 
the α GluClR structure (3RIF). As shown in Fig. 7D 
and E, this produced a binding orientation very 
similar to that seen in the crystal structure, 
suggesting that ivermectin binds in a similar pose to 
both receptors. This in turn suggests our original 
ELIC-based model placed interfacial M1 and M3 too 
close to allow ivermectin access to its binding site in 
the intersubunit cavity. Interestingly, we saw only 
slight differences in the orientation of ivermectin 
docked to WT and A288G GlyRs, coloured gray and 
green respectively in Fig. 7B and C, with only a 
slight shift to accommodate the extra bulk of the 
A288 methyl group. Its predicted binding energies to 
the WT and A288G models were also similar.  
 
Comparison of α1 GlyR with α GluClR ivermectin 
binding interactions 
 Fig. 8 shows a sequence alignment of M1, 
M2 and M3 domains of the α1 GlyR and the 
crystallized C. elegans α GluClR. It also includes 
several other GluClRs to be considered below. 
Using α GluClR numbering, L218, S260 and T285 
were seen to form crucial H-bonds with ivermectin 
in the crystal structure (10). These residues (plus 
their homologues in other receptors) are colored blue 
in the alignment while residues seen to form van der 
Waals interactions with ivermectin are colored 
green. The residues identified in the present study as 
crucial ivermectin determinants in the α1 GlyR (i.e., 
P230 and A288) are colored red.  
The H-bond with L218 is formed with the 
backbone carbonyl so its role in ivermectin binding 
is not readily tested by mutagenesis. Nevertheless, as 
the availability of the L218 carbonyl for H-bonding 
is due to helical disruption by the conserved M1 
proline one helical turn lower, it is likely that this 
bond is conserved in other Cys-loop receptors. 
As we had not probed the role of the M3 H-
bonding residue (T285 in α GluClR, L292 in α1 
GlyR) above, we investigated the effect of the 
L292T (α1 GlyR  α GluClR) mutation. If 
ivermectin binds identically to α1 GlyRs and α 
GluClRs, this mutation should introduce a H-bond 
that increases ivermectin affinity. On the other hand, 
even if no H-bond is formed, this mutation may 
enhance ivermectin affinity by increasing the space 
available for ivermectin to bind in the TMD 
interface crevice. The L292T mutant α1 GlyR was 
found to exhibit a mean ivermectin EC50 of 0.29 ± 
0.01 µM (n = 4 cells), significantly lower than that 
of the WT GlyR (P < 0.05). 
In the α GluClR structure, S260 (S15’) 
forms a H-bond with the ivermectin C05-OH that 
was proposed to be essential for direct agonist 
activation of Cys-loop receptors (10). Although our 
docking suggested a similar H-bond exists in the 
GlyR, we showed above that mutation of the 
equivalent residue S267I, which eliminates any H-
bonding propensity, had no effect on ivermectin 
sensitivity (Table 1), indicating this bond is either 
not important or is not present in the α1 GlyR.  
 
DISCUSSION 
 
Functional evidence for an α1 GlyR ivermectin 
binding site at the TMD subunit interface 
The A288F substitution abolished α1 GlyR 
sensitivity to both the direct agonist and glycine 
facilitatory effects of ivermectin. The P230W 
substitution in M1 decreased sensitivity to the direct 
ivermectin agonist effect by 7-fold in the WT GlyR 
and by 100-fold in the A288G mutant GlyR. The 
P230W mutation also decreased the glycine 
facilitatory effects of ivermectin (Table 3). 
Molecular modeling places A288 and P230 residues 
from the neighboring subunits into close proximity 
at the TMD intersubunit interface, at either side of 
the entrance to an interface cavity (Fig. 7). Our 
experiments employing heteromeric mutant subunits 
(Fig. 5) provide independent experimental support 
for an ivermectin site at this interface. However, 
computational docking using our ELIC-based GlyR 
model did not reveal a convincing binding site for 
ivermectin that would be significantly disrupted by 
either the A288F or P230W mutations. 
 
Selectivity of ivermectin analogues  
The most useful technique for functionally 
characterizing molecular interactions is mutant cycle 
analysis. Unfortuately, as commercially available 
ivermectin analogues invariably differ from one 
another by more than one molecular group, mutant 
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cycle analysis is not currently feasible for probing 
ivermectin binding interactions. We have previously 
shown that emamectin, eprinomectin, moxidectin 
and doramectin, which all vary from ivermectin at 
both disaccharide and spiroketal groups, exhibit 
simiar potencies to ivermectin at WT and A288-
substituted GlyRs (21). Selamectin, on the other 
hand, demonstrated a greatly decreased potency at 
the α1 GlyR and a moderately reduced potency at 
the α3B GluClR. Selamectin contains a 
monosaccharide instead of the disaccharide of 
ivermectin, a phenyl ring on the spiroketal and an 
oxime in place of the hydroxyl at C05. Its decreased 
potency suggests that the C05-OH is crucial for 
interactions with the TMD. This is reflected in the 
decreased anthelmintic potency of ivermectin 
analogues with C05 substituents (39,42). Consistent 
with this, our model predicted that the ivermectin 
C05-OH interacts with the TMD intersubunit site. 
 
Comparison of our functional data with the α 
GluClR crystal structure 
Although the entry to the TMD intersubunit 
cavity in our ELIC-based model was not wide 
enough for ivermectin to dock within, the α GluClR-
ivermectin crystal structure (10) clearly shows 
ivermectin lodged within this cavity. This structure 
provided a template for us to refine our modeling 
and docking of ivermectin to the GlyR, and our 
docking orientation proved very similar to that seen 
in the crystal structure (Fig. 7). The α GluClR-
ivermectin structure shows a distance of  9.4 Å 
between M1 and M3 (L218-G281 Cαs), whereas the 
corresponding distances in ELIC and GLIC are 7.4 
and 6.4 Å, respectively. Note that α GluClR and 
GLIC are in the putative open state, whereas ELIC is 
in the putative closed state. Thus cavity width does 
not appear to correlate with channel state although 
“wedging” the cavity open with ivermectin (10) 
certainly seems to favour channel opening. 
The GlyR A288G mutation dramatically 
lowered the ivermectin EC50 although docking 
studies showed only slight differences in binding 
orientations and predicted binding energies at WT 
and A288G GlyRs (Fig 7). Thus, our model provides 
no clear explanation for the observed EC50 
differences. We postulate that rather than affecting 
binding per se, the methyl group of A288 reduces 
access to the interface cavity and consequently 
reduces the on-rate and apparent affinity for 
ivermectin. The inhibition of access to the cavity 
would be greatly amplified in the A288F mutant, 
with the possible additional effect of direct steric 
inhibition of ivermectin binding. 
Hibbs and Gouaux identified a H-bond 
between S260 (S15’) and ivermectin C05-OH in the 
α GluClR that they proposed was crucial for both 
high ivermectin affinity and direct agonist efficacy. 
However, we showed this bond is not required for 
high affinity ivermectin activation of the α1 GlyR. 
Moreover, because the H. contortus α GluClR, the 
C. elegans α3B GluClR and the H. contortus α3B 
GluClR all contain endogenous Alas at the 
corresponding 15’ position (Fig. 8) and are at least 
as ivermectin-sensitive as the α GluClR (40,43), it is 
evident that this H-bond is not necessarily required 
for high ivermectin sensitivity or direct ivermectin 
activation in those receptors as well. If a slightly 
greater distance cut-off is allowed for defining H-
bonds, then other potential H-bonds can be 
identified between ivermectin C05-OH and Q219 in 
M1 and N264 in M2 of the α GluClR structure, and 
equivalent residues Q226 and R271 in our 3RIF-
based GlyR model. Perhaps these H-bonds render 
the H-bond with S15’ functionally redundant. 
Hibbs and Gouaux also identified a crucial 
H-bond between the ivermectin spiroketal oxygen 
and an M3 Thr (T285 using α GluClR numbering). 
As the α1 GlyR contains a non-H-bonding leucine 
(L292) at the corresponding position (Fig. 8), it is 
evident this H-bond is not required for high 
ivermectin sensitivity at the WT or A288G α1 
GlyRs. Moreover, as several other GluClRs contain 
an endogenous Alas at this position (Fig. 8), it is 
evident this H-bond is not required for high 
ivermectin sensitivity at some GluClRs as well. 
Nevertheless, we found that the α1 GlyR L292T 
mutation did increase ivermectin sensitivity, 
possibly consistent with a role for this H-bond.  
The third H-bond, between ivermectin and 
the L218 backbone of the α GluClR, occurs because 
of the break in the helix due to the highly-conserved 
M1 Pro. As the α1 GlyR contains this Pro and a 
conserved residue (I225) at the Leu position, we 
infer the same H-bond bond is likely to exist in the 
α1 GlyR. Although not directly testable by 
conventional mutagenesis, our data (Tables 1 and 3) 
and docking studies are consistent with this notion.  
Finally, Hibbs and Gouaux reported a 
network of van der Waals interactions between the 
ivermectin disaccharides and residues in the α 
GluClR M2-M3 loop that they thought might be 
important for allosteric interactions with the LBD 
(10). We have previously reported that moxidectin, 
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which lacks both sugars, is equipotent with 
ivermectin at the α1 GlyR (21), arguing against a 
crucial role for these interactions in the GlyR.  
 
Ivermectin gating determinants at the LBD-TMD 
interface 
If ivermectin interacts with the TMD of the 
α1 GlyR, why is its ability to open the channel 
affected by mutations at the LBD-TMD interface? 
The L142C, Y222C and Y279F mutations each 
caused a large rightward shift in the ivermectin 
activation EC50, although ivermectin facilitation of 
glycine currents showed a similar sensitivity as seen 
in the WT GlyR. The same mutations also produced 
large rightward shifts in glycine activation EC50 
values (Table 2). Similar effects on ivermectin and 
glycine sensitivities were observed when the above 
three mutations were investigated on the background 
of the A288G mutation. Together, these results 
strongly suggest that the L142C, Y222C and Y279F 
mutations do not disrupt an ivermectin binding site 
but rather reduce ivermectin gating efficacy. This is 
consistent with the known roles of the conserved 
Cys-loop, the pre-M1 domain and the M2-M3 
domain in gating the GlyR (44) and suggests that 
ivermectin activation involves a global 
conformational change that propagates to the LBD 
rather than simply a localized TMD conformational 
change. We therefore speculate that other ivermectin 
sensitivity determinants that have previously been 
identified in the TMD and interfacial domains of 
GluClRs (7,9,40) also disrupt the gating rather than 
the binding mechanisms of ivermectin.   
 
Allosteric effects of TMD mutations near the 
ivermectin site 
The P230W mutation decreased both 
glycine sensitivity and ivermectin sensitivity. It 
appears the dominant effect of this mutation is to 
rearrange the M1 helix so as to abolish the H-bond 
between ivermectin and the I225 backbone. It is 
interesting that the Q226C, P230W and I234W 
mutant GlyRs all showed decreased glycine 
sensitivities (with no function at all for I234W) 
compared to the I225W, I229W and L233W mutant 
GlyRs, suggesting that the effects of P230W are not 
specific to ivermectin. However, the decrease in 
glycine sensitivity caused by the Trp-substitution at 
Q226, P230 and I234 might simply reflect their 
apposition with M3 of the adjacent subunit, whereas 
the Trp-substitutions at I225, I229 and L233 are less 
disruptive because their sidechains are directed 
towards the surrounding lipids (45). 
The threshold concentrations at which 
ivermectin begins to enhance desensitization at 
L233W and L291W mutant GlyRs are 1-10 µM, not 
remarkably different from WT ivermectin EC50 
values. The glycine sensitivities of both mutant 
receptors are also significantly higher than WT GlyR 
values (Table 2). The nonconservative L233Q and 
L291Q substitutions had no effect on the mode of 
action of ivermectin, implying that the large 
hydrophobic Trp sidechain is required for this effect, 
potentially blocking the conformational change 
normally favoured by ivermectin. We therefore 
conclude that ivermectin binds with normal affinity 
to the L233W and L291W mutant GlyRs but 
promotes a desensitized state, rather than an open 
state. From our results, it is unclear if this effect is 
due to an altered ivermectin binding conformation 
imposed by the Trp-substitutions or a preference of 
these mutants for a glycine-bound desensitized state. 
 
Conclusion 
Our docking simulations predict that 
ivermectin binds to the α1 GlyR in a similar pose as 
observed in the α GluClR crystal structure. 
Ivermectin binding to the α GluClR was shown to 
mediated by H-bonds with L218, S260 and T285 
and a network of van der Waals interactions (10). 
We showed that H-bonds with residues equivalent to 
S260 and T285 are not required for high ivermectin 
sensitivity at either the α1 GlyR or three other 
GluClRs. As the H-bond with the L218 or 
equivalent residues (e.g., GlyR I225) is via the 
carbonyl backbone, its role cannot be readily tested 
and is likely to be conserved along with the 
conserved Pro that exposes this carbonyl. We also 
show that van der Waals interactions between the 
ivermectin sugars and α1 GlyR M2-M3 loop 
residues are not important for high ivermectin 
affinity or efficacy.  
The α1 GlyR A288F mutation eliminated 
the direct activation and glycine-potentiating effects 
of ivermectin, presumably by blocking access to the 
cavity. The effect of this mutation contrasted with 
those of several mutations in the conserved Cys-
loop, pre-M1 domain and M2-M3 loop that 
disrupted only the direct activation, but not the 
glycine-enhancing, effects of ivermectin. We 
conclude these later residues disrupted ivermectin 
gating efficacy, consistent with the known role of 
this domain in mediating glycine agonist 
transduction.  
In summary, our results indicate that the 
ivermectin-binding mechanisms as revealed by the α 
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GluClR structure cannot be generalized to other 
Cys-loop receptors with comparable ivermectin 
sensitivities. Understanding these mechanisms will 
be crucial for designing new drugs as anthelmintics 
and as therapies for a wide range of human 
neurological disorders. 
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FIGURE LEGENDS 
 
Figure 1. Residues at the LBD-TMD interface influence ivermectin efficacy. A. Cysteine scan of M2-M3 loop 
residues showing mean steady-state currents activated by 0.3 (squares), 3 (open triangles) and 30 (filled circles) 
µM ivermectin as a fraction of those activated by 10 mM glycine. Only P275C and Y279F significantly 
disrupted ivermectin efficacy. B. Locations of interfacial residues influencing ivermectin efficacy. Two 
orthogonal views of the interfacial region are shown. C. Sample ivermectin dose-response relationships at the 
WT, Y279F and L142C GlyRs. In this and all subsequent figures, glycine and ivermectin applications are shown 
as filled and unfilled bars, respectively. D. Examples of ivermectin potentiation of glycine responses at the WT 
and L142C GlyRs. Ivermectin was applied for 5 s intervals at the indicated concentrations. E. Averaged 
ivermectin activation dose-response relationships at the WT, L142C, Y222C, P275C and Y279F GlyRs. F. 
Averaged ivermectin potentiation dose-response relationships at the same GlyRs.  
 
Figure 2. The A288F mutation eliminates ivermectin enhancement of glycine currents. A. Example showing the 
low potency of ivermectin potentiation of glycine responses at the A288F GlyR. F. Averaged ivermectin 
potentiation dose-response relationships at the A288F and WT GlyRs.  
 
 12 
Figure 3. Ivermectin sensitivity of GlyRs incorporating mutations in the transmembrane domains. A. Averaged 
glycine (left) and ivermectin (right) dose-response relationships of GlyRs incorporating mutations in the M1 
domain. B. Averaged glycine (left) and ivermectin (right) dose-response relationships of GlyRs incorporating 
mutations in the M2 or M3 domains. C. Sample ivermectin dose-response relationships at the I229W, P230W 
and L233W mutant GlyRs. Note lack of ivermectin activation and enhanced glycine desensitization at the 
L233W mutant GlyR.  
 
Figure 4. Inhibitory effects of ivermectin at L233W, L291W and T264W mutant GlyRs. A. Ivermectin has no 
agonist effect but enhances the desensitization rate of glycine-gated currents at the L233W and L291W mutant 
GlyRs. B. Averaged time to half decay (t1/2) of glycine-gated currents before and after ivermectin application for 
the experiments shown in A. C. Glycine produces a concentration-dependent transient inward current followed 
by a sustained inhibition of a leak current at the T264W mutant GlyR. Ivermectin produced an irreversible dose-
dependent inhibition of this leak current. 
 
Figure 5. Ivermectin responses at GlyRs formed by co-expression of A288F and P230W/A288G double mutant 
GlyRs. A. Sample glycine- and ivermectin-gated currents at the mixed receptor. B. Averaged ivermectin dose-
response relationships at each of the indicated receptors. Note that co-expression of the two ivermectin-
insensitive receptors produces a receptor with high ivermectin sensitivity (unfilled circles).  
 
Figure 6. Effects of selamectin on GlyRs and GluClRs. A. Selamectin does not directly activate GlyRs although 
it did potentiate glycine responses. B. Averaged selamectin and ivermectin potentiation dose-response 
relationships at the WT GlyR. C. Sample selamectin dose-response relationship at the GluClR. D. Averaged 
ivermectin and selamectin activation dose-response relationships at the GluClR and WT and A288G GlyRs.  
 
Figure 7. Docking of ivermectin to molecular models of the α1 GlyR based on ELIC (2VL0) and α GluClR 
(3RIF). A. Surface representation of two subunits of the GlyR model, colored cyan and orange, viewed with the 
ECD at the top. The membrane exposed surface of the TMD is lighter in color. Residues A288 and P230 are 
shown in red and magenta respectively. Residues surrounding P230, I225, Q226 and I229 are shown in light 
pink and residues L233 and L291 from opposing subunits are shown in yellow B. Closer view of the region 
surrounding these two residues, with best docks of ivermectin at the WT and A288G mutant GlyRs shown in 
grey and green respectively. C. Ivermectin is docked as in B but the model is rotated 90° to be viewed from the 
extracellular space with the membrane plane parallel to the plane of the page and a slice taken through the model 
to reveal a cavity at the subunit interface with the entrance bordered by A288 and P230 and residues T264(+), 
shown in green, and Q266(-), shown in blue, contributing to the lining of the cavity. 
 
Figure 8. Amino acid sequence alignment of TMDs 1-3 for the indicated anionic Cys-loop receptors. The Uni-
prot ID codes are shown for all sequences. Residues shown in blue are homologous with those that mediate H-
bonding in the crystallized C. elegans α GluClR. Residues shown in green form van der Waal interactions with 
ivermectin. P230 and A288 in the α1 GlyR are colored red. All four GluClRs included here share similar 
ivermectin sensitivities (25,40,43). 
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Table 1 – Direct agonist effects of ivermectin on WT and mutant GlyRs 
 
Receptor EC50 (µM) nH Imax (nA) n 
WT 1.8 ± 0.2 2.7 ± 0.4 5.6 ± 0.8 5 
A52C 1.7 ± 0.4 3.0 ± 0.4 5.6 ± 0.4 4 
E53C 1.1 ± 0.2 3.5 ± 0.3 4.5 ± 1.1 4 
D141G 1.0 ± 0.2 2.9 ± 0.3 5.5 ± 0.7 4 
L142C 19 ± 3.0aaa 2.5 ± 0.3 1.9 ± 0.8aa 5 
K143C 1.1 ± 0.2 3.4 ± 0.9 4.5 ± 0.2 4 
Y222C 22 ± 1.4aaa 2.5 ± 0.1 3.9 ± 0.4 4 
Y222F 2.1 ± 0.2 2.6 ± 0.2 5.2 ± 0.4 4 
Y223C 2.6 ± 0.3 2.3 ± 0.3 4.5 ± 0.5 4 
Y223F 2.8 ± 0.6 2.6 ± 0.3 4.9 ± 0.2 4 
L224F 2.4 ± 0.4 2.5 ± 0.2 4.6 ± 0.6 4 
I225C 3.6 ± 1.1 1.8 ± 0.1 3.5 ± 0.2 4 
I225W 2.5 ± 0.8 2.6 ± 0.8 6.2 ± 0.3 4 
Q226W 2.1 ± 0.2 4.7 ± 0.8a 9.9 ± 0.7aa 4 
Q226C 4.3 ± 0.4aaa 3.0 ± 0.4 4.8 ± 0.5 4 
M227C 1.9 ± 0.5 2.9 ± 0.6 6.1 ± 1.1 4 
I229W 1.7 ± 0.3 3.2 ± 0.2 7.8 ± 0.9 4 
P230W 13 ± 2.8aaa 4.0 ± 0.9 1.6 ± 0.4aa 4 
L233W inhibition – see text  5 
L233Q 1.4 ± 0.4 2.7 ± 0.3 4.5 ± 1.1 3 
I234W no expression  10 
V260W 2.8 ± 0.6 2.6 ± 0.7 5.0 ± 1.8 4 
T264W inhibition – see text  5 
Q266W 0.38 ± 0.08a 2.2 ± 0.3 3.9 ± 0.6 4 
S267I 1.8 ± 0.2 4.2 ± 0.8 8.2 ± 1.3 4 
P275C > 10 nd nd 4 
Y279C 1.4 ± 0.3 2.6 ± 0.7 7.1 ± 0.7 3 
Y279F 13 ± 0.4aaa 3.3 ± 0.1 6.8 ± 0.4 5 
W286F 3.8 ± 0.6a 4.2 ± 0.2a 4.3 ± 0.5 4 
A288G 0.032 ± 0.008 1.8 ± 0.4 4.3 ± 0.2 4 
L291W Inhibition – see text  5 
L291Q 1.5 ± 0.3 3.5 ± 0.5 4.0 ± 0.6 4 
S296W 2.1 ± 0.3 2.7 ± 0.6 3.4 ± 0.3 3 
 
a P<0.05, aaP<0.01. aaa P<0.001 by unpaired t-test relative to WT GlyR values 
nd – not determined
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 Table 2 - Agonist effects of glycine on WT and mutant GlyRs  
 
Receptor EC50 (µM) nH Imax (nA) n 
WT 34 ± 3 2.6 ± 0.2 12 ± 1 6 
L142C 5900 ± 1400aaa 1.7 ± 0.2a 0.6 ± 0.2aaa 4 
Y222C 9800 ± 2800aaa 1.4 ± 0.3aa 1.5 ± 0.5aaa 4 
Y222F 110 ± 20aaa 2.4 ± 0.6 16 ± 3 4 
I225W 11 ± 2aaa 2.8 ± 0.1 13 ± 2 4 
Q226W 360 ± 18aaa 1.7 ± 0.1aa 11.0 ± 1.3 4 
I229W 110 ± 12aaa 1.8 ± 0.1a 12 ± 2 4 
P230W 260 ± 19aaa 1.6 ± 0.1aa 4.8 ± 1.5aa 4 
L233W 18 ± 5a 2.1 ± 0.3 14 ± 3 4 
L233Q 240 ± 10aaa 2.5 ± 0.3 4.6 ± 0.7aaa 5 
I234W no expression - 10 
V260W 20 ± 1 2.7 ± 0.4 1.8 ± 0.1aaa 4 
T264W 27 ± 2 2.1 ± 0.6 2.7 ± 1.0aaa 3 
Q266W 28 ± 3 2.0 ± 0.3 8.0 ± 2.1 4 
P275C 1500 ± 300aaa 1.8 ± 0.3 3.0 ± 0.7aaa 5 
Y279F 3600 ± 700aaa 1.6 ± 0.1aa 4.4 ± 1.1a 7 
A288G 6.0 ± 1.3aaa 0.9 ± 0.3aa 4.8 ± 0.7aaa 4 
L291W 19 ± 2aa 1.5 ± 0.1aa 16 ± 3 4 
L291Q 19 ± 3a 1.5 ± 0.2aa 9.8 ± 1.5 4 
A288G/L142C 420 ± 55bbb 1.2 ± 0.2 1.0 ± 0.3bbb 5 
A288G/Y222C 1020 ± 70bbb 1.5 ± 0.1 4.8 ± 0.6 4 
A288G/Y279F 480 ± 26bbb 2.7 ± 0.1bb 11.3 ± 0.9bb 4 
     
     
     
 
a P<0.05, aaP<0.01. aaa P<0.001 by unpaired t-test relative to WT GlyR values 
b P<0.05, bbP<0.01. bbb P<0.001 by unpaired t-test relative to A288G mutant GlyR values 
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Table 3 – Facilitation by ivermectin of EC5-10 glycine-activated currents 
 
Receptor EC50 (µM) nH n 
WT 2.1 ± 0.5 2.3 ± 0.3 5 
L142C 0.9 ± 0.1a 1.7 ± 0.1 6 
Y222C 1.3 ± 0.3 3.2 ± 0.2 4 
P230W 5.4 ± 0.5aa 2.7 ± 0.6 4 
P275C 3.5 ± 0.7 2.0 ± 0.4 4 
Y279F 0.6 ± 0.1a 2.0 ± 0.3 4 
S267I 1.5 ± 0.3 2.7 ± 0.2 3 
a P<0.05, aaP<0.01. aaa P<0.001 by unpaired t-test relative to WT GlyR values 
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Table 4 – Direct agonist effects of ivermectin on GlyR mutants incorporating A288G 
 
Receptor EC50 (µM) nH Imax (nA) n 
A288G 0.032 ± 0.008 1.8 ± 0.4 4.3 ± 0.2 4 
A288G/L142C 0.9 ± 0.1 aaa 3.5 ± 0.1a 6.8 ± 2.4 4 
A288G/Y222C 2.4 ± 0.5aa 2.5 ± 0.2 4.9 ± 0.3 5 
A288G/I225W 0.15 ± 0.02aa 3.7 ± 0.2aa 6.5 ± 0.7a 3 
A288G/Q226W 0.15 ± 0.02aa 3.2 ± 0.4 5.8 ± 0.6a 3 
A288G/I229W 0.24 ± 0.02aaa 4.0 ± 0.4a 6.0 ± 0.7a 3 
A288G/P230W 5.6 ± 0.3aaa 2.3 ± 0.4 4.7 ± 0.8 4 
A288G/L233W inhibition – see text  4 
A288G/I234W no expression  10 
A288G/Y279F 0.7 ± 0.2a 3.0 ± 0.8 8.6 ± 1.1a 6 
A288G/L291W inhibition – see text  4 
 
a P<0.05, aaP<0.01. aaa P<0.001 by unpaired t-test relative to WT GlyR values 
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     _______________________       ________________________
220  MGYYLIQMYIPSLLIVILSWISFWINMDAAPARVGLGITTVLTMTTQSSGSRAS   α1 GlyR HUMAN
213  FSFYLLQLYIPSCMLVIVSWVSFWFDRTAIPARVTLGVTTLLTMTAQSAGINSQ   α GluCl CAEEL cryst
247  FSYYLLQLYIPSFMLVAVSWVSFWLDKDSVPARVTLGVTTLLTMTTQASGVNAN   α GluCl HAECO
253  YSYYLIQLYIPCIMLVVVSWVSFWLDKDAVPARVSLGVTTLLTMTTQASGINTK   α3B GluCl CAEEL
261  YSYYLIQLYIPCIMLLVVSWVSFWLDKDAVPARVSLGVTTLLTMTTQASGINSK   α3B GluCl HAECO
    
           _____________________________
274  LPKVSYVKAIDIWMAVCLLFVFSALLEYAAVNFVS   α1 GlyR HUMAN       P23415
267  LPPVSYIKAIDVWIGACMTFIFCALLEFALVNHIA   α GluCl CAEEL cryst   O17793
301  LPPVSYTKAIDIWIGVCLAFIFGALLEFALVNWAA   α GluCl HAECO         Q9TZR3
307  LPPVSYIKAVDVWIGVCLAFIFGALLEYAVVNYYG   α3B GluCl CAEEL       Q17369
315  LPPVSYIKAVDVWIGVCLAFIFGALLEYAVVNYYG   α3B GluCl HAECO       O46124
M1 M2
M3
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